Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial
Authors
Keywords
-
Journal
BMC Complementary Medicine and Therapies
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-19
DOI
10.1186/s12906-023-03948-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-alcoholic fatty liver disease
- (2021) Elizabeth E Powell et al. LANCET
- Danggui-Shaoyao-San Improves Gut Microbia Dysbiosis and Hepatic Lipid Homeostasis in Fructose-Fed Rats
- (2021) Jing Yin et al. Frontiers in Pharmacology
- Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- Epidemiological feature of NAFLD from 1999 to 2018 in China
- (2020) Jianghua Zhou et al. HEPATOLOGY
- Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
- (2020) Jonathan G. Stine et al. Clinical Gastroenterology and Hepatology
- Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
- (2019) Feng Zhou et al. HEPATOLOGY
- NAFLD in children: new genes, new diagnostic modalities and new drugs
- (2019) Valerio Nobili et al. Nature Reviews Gastroenterology & Hepatology
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
- (2018) Jian Gao Fan et al. Journal of Digestive Diseases
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
- (2016) Janki Patel et al. Therapeutic Advances in Gastroenterology
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
- (2013) A.-W. Chan et al. BMJ-British Medical Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started